Search

Your search keyword '"Luxturna (Medication) -- Reports"' showing total 19 results
Start Over Descriptor "Luxturna (Medication) -- Reports"
19 results on '"Luxturna (Medication) -- Reports"'

1. Gene And Cell Therapies In Rare Disorder Market Size in the 7MM was ~USD 2000 Million in 2023, estimated DelveInsight

Subjects
Novartis AG -- Forecasts and trends, Business -- Research, BCG vaccines -- Forecasts and trends -- Reports, Genes -- Reports -- Forecasts and trends, BCG -- Forecasts and trends -- Reports, Epidemiology -- Forecasts and trends -- Reports, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, Business, international, Luxturna (Medication) -- Reports, Zolgensma (Medication) -- Reports
Abstract

M2 PRESSWIRE-June 14, 2024-: Gene And Cell Therapies In Rare Disorder Market Size in the 7MM was ~USD 2000 Million in 2023, estimated DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:13062024 DelveInsight's 'Cell [...]

Published
2024

2. Luxturna (Voretigene neparvovec-rzyl) Drug Insights and Market Forecasts 2017-2030

Subjects
Voretigene neparvovec -- Reports, General interest, News, opinion and commentary, Luxturna (Medication) -- Reports
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Luxturna (Voretigene neparvovec-rzyl) - Drug Insight and Market Forecast - 2030' report has been added to ResearchAndMarkets.com's offering. Luxturna [...]

Published
2020

4. Luxturna (Voretigene neparvovec-rzyl) Drug Insights and Market Forecasts 2017-2030

Subjects
Voretigene neparvovec -- Reports, Business, Business, international, Luxturna (Medication) -- Reports
Abstract

M2 PRESSWIRE-November 4, 2020-: Luxturna (Voretigene neparvovec-rzyl) Drug Insights and Market Forecasts 2017-2030 (C)1994-2020 M2 COMMUNICATIONS RDATE:04112020 The 'Luxturna (Voretigene neparvovec-rzyl) - Drug Insight and Market Forecast - 2030' report [...]

Published
2020

5. Luxturna (voretigene neparvovec-rzyl) - Drug Insight and Market Forecast - 2030

Subjects
Voretigene neparvovec -- Reports -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business, Luxturna (Medication) -- Reports
Abstract

New York, Aug 26, 2020 (GLOBE NEWSWIRE via COMTEX) -- Reportlinker.com announces the release of the report 'Luxturna (voretigene neparvovec-rzyl) - Drug Insight and Market Forecast - 2030' - https://www.reportlinker.com/p05865975/?utm_source=GNW [...]

Published
2020

6. 7MM Retinitis Pigmentosa (RP) Market Insights, 2017-2030 - United States, Germany, France, Italy, Spain, United Kingdom, and Japan

Subjects
Voretigene neparvovec -- Reports -- Forecasts and trends, BCG -- Forecasts and trends -- Reports, Brand equity -- Forecasts and trends -- Reports, French foreign relations -- Forecasts and trends -- Reports, Retinitis pigmentosa -- Forecasts and trends -- Reports, Epidemiology -- Reports -- Forecasts and trends, Market trend/market analysis, General interest, News, opinion and commentary, Luxturna (Medication) -- Reports
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Retinitis Pigmentosa (RP) - Market Insights, Epidemiology, and Market Forecast - 2030' drug pipelines has been added to ResearchAndMarkets.com's [...]

Published
2020

7. Retinitis Pigmentosa (RP): Global Market Insights, Epidemiology and Forecast to 2030

Subjects
Voretigene neparvovec -- Reports -- Forecasts and trends, BCG -- Forecasts and trends -- Reports, Brand equity -- Forecasts and trends -- Reports, Retinitis pigmentosa -- Forecasts and trends -- Reports, Epidemiology -- Reports -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business, Luxturna (Medication) -- Reports
Abstract

Dublin, June 24, Jun 24, 2020 (GLOBE NEWSWIRE via COMTEX) -- The 'Retinitis Pigmentosa (RP) - Market Insights, Epidemiology, and Market Forecast - 2030' drug pipelines has been added to [...]

Published
2020

8. EMA|CAT|643189|2018 Inspections, Human Medicines Pharmacovigilance and Committees Division CAT monthly report of application procedures, guidelines and related documents on advanced therapies

Subjects
Voretigene neparvovec -- Reports, Drugs -- Reports -- Inspection, Web sites (World Wide Web), Business, international, Luxturna (Medication) -- Reports
Abstract

Amsterdam: European Medicines Agency has issued the following document: 30 Churchill Place * Canary Wharf * London E14 5EU * United Kingdom An agency of the European Union Telephone +44 [...]

Published
2019

9. Global Gene Therapy Market Forecast to Hit $363 Million by 2022

Subjects
Axicabtagene ciloleucel -- Reports, Gene therapy -- Reports, Tisagenlecleucel -- Reports, Genes -- Reports, Voretigene neparvovec -- Reports, Hemophilia -- Reports, Pharmaceutical industry, HIV, General interest, News, opinion and commentary, Kymriah (Medication) -- Reports, Luxturna (Medication) -- Reports, Yescarta (Medication) -- Reports
Abstract

PUNE: ReportsnReports has issued the following news release: Global Gene Therapy Market Analysis & Forecast to 2022 Research Report added in ReportsnReports. Growing at a CAGR of over x% the [...]

Published
2019

10. Global Gene Therapy Market Forecast to Hit $363 Million by 2022

Subjects
Genes -- Reports, Gene therapy -- Reports, Business, News, opinion and commentary, Yescarta (Medication) -- Reports, Luxturna (Medication) -- Reports, Kymriah (Medication) -- Reports
Abstract

PUNE, India, March 8, 2019 /PRNewswire/ -- Global Gene Therapy Market Analysis & Forecast to 2022 Research Report added in ReportsnReports. Growing at a CAGR of over x% the global [...]

Published
2019

11. Gene Editing and Gene Therapy Breakthroughs 2018: Drug Approvals of Yescarta, Luxturna and Kymriah have Turned a Leaf in the Pharmaceutical Chapter of Gene Therapy Development

Subjects
Gene therapy -- Reports, Genes -- Reports, Drug approval -- Reports, Banking, finance and accounting industries, Business, Yescarta (Medication) -- Reports, Luxturna (Medication) -- Reports, Kymriah (Medication) -- Reports
Abstract

Dublin, Oct 16, 2018 (GLOBE NEWSWIRE via COMTEX) -- The 'Gene Editing and Gene Therapy Breakthroughs Propelling Mainstream Treatments' report has been added to ResearchAndMarkets.com's offering. The drug approvals of [...]

Published
2018

12. Gene Therapy Market, 2018-2030 - Analysis & Research Report Featuring Approx 450 Companies

Subjects
Novartis AG -- Forecasts and trends -- Reports, Innovation Network Corporation of Japan -- Forecasts and trends -- Reports, Sanofi S.A. -- Forecasts and trends -- Reports, Genes -- Reports, Gene therapy -- Reports, Pharmaceutical industry -- Forecasts and trends -- Reports, Market trend/market analysis, Business, News, opinion and commentary, Luxturna (Medication) -- Reports
Abstract

DUBLIN, Aug. 13, 2018 /PRNewswire/ -- The 'Gene Therapy Market (2nd Edition), 2018-2030' report has been added toResearchAndMarkets.com's offering. The year 2017 was particularly eventful; despite the withdrawal of Glybera [...]

Published
2018

13. Gene Therapies: A Growing Pipeline and Approval of CAR-T Cell Therapies Reflect Increasing Commercial Appeal, Despite Difficulties Faced by products such as Glybera and Strimvelis

Subjects
Pipe lines -- Reports, T cells -- Reports, Genes -- Reports, Gene therapy -- Reports, Business, News, opinion and commentary, Luxturna (Medication) -- Reports, Kymriah (Medication) -- Reports
Abstract

NEW YORK, July 18, 2018 /PRNewswire/ --Gene Therapies: A Growing Pipeline and Approval of CAR-T Cell Therapies Reflect Increasing Commercial Appeal, Despite Difficulties Faced by products such as Glybera and [...]

Published
2018

14. Gene Therapy Market, 2018-2030 - ResearchAndMarkets.com

Subjects
Gene therapy -- Reports, Genes -- Reports, Business, Business, international, Luxturna (Medication) -- Reports
Abstract

DUBLIN -- The 'Gene Therapy Market (2nd Edition), 2018-2030' report has been added to ResearchAndMarkets.com's offering. The Gene Therapy Market (2nd Edition), 2018-2030 report provides an extensive study on the [...]

Published
2018

15. Gene Therapy Market, 2018-2030

Subjects
Gene therapy -- Reports, Genes -- Reports, Business, Business, international, Luxturna (Medication) -- Reports
Abstract

M2 PRESSWIRE-May 2, 2018-: Gene Therapy Market, 2018-2030 (C)1994-2018 M2 COMMUNICATIONS RDATE:02052018 The 'Gene Therapy Market (2nd Edition), 2018-2030' report has been added to ResearchAndMarkets.com's offering. The Gene Therapy Market [...]

Published
2018

16. Global Gene Therapy Market Analysis & Forecast to 2022

Subjects
Genes -- Reports, Gene therapy -- Reports, Hemophilia -- Reports, Business, News, opinion and commentary, Yescarta (Medication) -- Reports, Luxturna (Medication) -- Reports, Kymriah (Medication) -- Reports
Abstract

Growing at a CAGR of over x% the global gene therapy market is forecast to hit $363 million by 2022 from $x million in 2017. Strengthened by recent approvals of [...]

Published
2018

17. $850,000 GENE THERAPY NOT WORTH IT, REPORT SHOWS

Subjects
Health care costs -- Reports, Gene therapy -- Reports, Genes -- Reports, News, opinion and commentary, Luxturna (Medication) -- Reports
Abstract

WASHINGTON, DC -- The following information was released by Public Citizen: Statement of Peter Maybarduk, Director of Public Citizen's Access to Medicines Program Note: A new report from the Institute [...]

Published
2018

18. ICER says Luxturna is not cost-effective

Subjects
Business, Business, international, Luxturna (Medication) -- Reports
Abstract

M2 PRESSWIRE-January 15, 2018-: ICER says Luxturna is not cost-effective (C)1994-2018 M2 COMMUNICATIONS RDATE:12012018 In an evidence report published Friday, the Institute for Clinical and Economic Review said vision loss [...]

Published
2018

19. Luxturna to open gene therapies market: analyst

Subjects
United States. Food and Drug Administration -- Reports -- International economic relations, Hemophilia -- Reports, Gene therapy -- Reports, Genes -- Reports, Business, international, Luxturna (Medication) -- Reports
Abstract

The latest approval by the U.S. Food and Drug Administration for Luxturna, a new gene therapy to treat hereditary retinal degeneration, will prompt other gene therapies to commercialize, an analyst [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results